Brief: Abbisko Cayman H1 Revenue RMB 497 Million
10/07/2024 13:02
Jul 10 (Reuters) - Abbisko Cayman H1 revenue RMB 497 million
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration